HealthCor Management L.P. acquired a new position in shares of Stryker Co. (NYSE:SYK) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 166,280 shares of the medical technology company’s stock, valued at approximately $25,747,000. Stryker comprises 0.8% of HealthCor Management L.P.’s investment portfolio, making the stock its 29th largest holding.
Several other institutional investors have also recently added to or reduced their stakes in the company. San Francisco Sentry Investment Group CA increased its stake in shares of Stryker by 47.8% during the 3rd quarter. San Francisco Sentry Investment Group CA now owns 1,005 shares of the medical technology company’s stock worth $143,000 after purchasing an additional 325 shares during the last quarter. Advisor Partners LLC increased its stake in shares of Stryker by 7.2% during the 4th quarter. Advisor Partners LLC now owns 4,827 shares of the medical technology company’s stock worth $779,000 after purchasing an additional 326 shares during the last quarter. Putnam FL Investment Management Co. increased its stake in shares of Stryker by 0.7% during the 4th quarter. Putnam FL Investment Management Co. now owns 44,867 shares of the medical technology company’s stock worth $6,947,000 after purchasing an additional 332 shares during the last quarter. Founders Capital Management LLC increased its stake in shares of Stryker by 1.4% during the 4th quarter. Founders Capital Management LLC now owns 25,790 shares of the medical technology company’s stock worth $3,993,000 after purchasing an additional 350 shares during the last quarter. Finally, LS Investment Advisors LLC increased its stake in shares of Stryker by 3.6% during the 4th quarter. LS Investment Advisors LLC now owns 10,249 shares of the medical technology company’s stock worth $1,587,000 after purchasing an additional 354 shares during the last quarter. Institutional investors own 75.71% of the company’s stock.
In other news, VP Katherine Ann Owen sold 3,700 shares of the company’s stock in a transaction that occurred on Monday, March 5th. The shares were sold at an average price of $161.66, for a total transaction of $598,142.00. Following the completion of the sale, the vice president now owns 7,596 shares of the company’s stock, valued at approximately $1,227,969.36. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Howard E. Cox, Jr. sold 7,400 shares of the company’s stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $164.09, for a total transaction of $1,214,266.00. The disclosure for this sale can be found here. Insiders sold a total of 20,390 shares of company stock valued at $3,324,962 in the last three months. Insiders own 7.40% of the company’s stock.
Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.95 by $0.01. The firm had revenue of $3.47 billion during the quarter, compared to the consensus estimate of $3.42 billion. Stryker had a net margin of 8.20% and a return on equity of 24.56%. The business’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.78 EPS. equities research analysts expect that Stryker Co. will post 7.12 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 30th. Shareholders of record on Thursday, March 29th will be issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 1.13%. The ex-dividend date is Wednesday, March 28th. Stryker’s dividend payout ratio is currently 70.15%.
Several research firms have recently weighed in on SYK. SunTrust Banks restated a “buy” rating and set a $179.00 price objective (up from $161.00) on shares of Stryker in a research note on Friday, January 26th. Cantor Fitzgerald reiterated a “hold” rating and issued a $163.00 price target on shares of Stryker in a research note on Tuesday, January 30th. Needham & Company LLC reiterated a “hold” rating on shares of Stryker in a research note on Wednesday, January 31st. Citigroup upgraded shares of Stryker from a “sell” rating to a “neutral” rating and upped their price target for the company from $165.77 to $166.00 in a research note on Tuesday, February 27th. Finally, Leerink Swann upped their price target on shares of Stryker from $177.00 to $184.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and fifteen have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $163.85.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/03/12/166280-shares-in-stryker-co-syk-acquired-by-healthcor-management-l-p.html.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.